Apimeds Pharmaceuticals Us, INC. (APUS) — 10-Q Filings
All 10-Q filings from Apimeds Pharmaceuticals Us, INC.. Browse 3 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (3)
-
Apimeds' Losses Mount Amid R&D Surge, IPO Boosts Cash to $7M
— Nov 12, 2025 Risk: high
Apimeds Pharmaceuticals US, Inc. (APUS) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $4,845,845, up from $ -
Apimeds Pharmaceuticals Files Q2 2025 10-Q
— Aug 19, 2025 Risk: low
Apimeds Pharmaceuticals US, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2025. The company, incorporated in Delaware with its prin -
Apimeds Pharmaceuticals Files Q1 2025 10-Q
— May 20, 2025 Risk: low
Apimeds Pharmaceuticals US, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Delaware with its pri
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX